在 Becker Law Group (贝克法律集团)，由 Todd Becker 律师领军，我们始终站在保护个人免受企业过失侵害的前线。目前，我们正密切关注针对 Ozempic (诺和泰)、Wegovy 和 Mounjaro 等 GLP-1 受体激动剂类药物的全国性诉讼。截至 2026 年 5 月，成千上万的患者指控制药巨头未能充分告知其产品可能导致严重的、改变人生的胃肠道侧反应。我们的使命是确保“您的抗争，就是我们的抗争”，在法律面前维护患者的安全权益。

什么是“胃轻瘫” (Gastroparesis)？

胃轻瘫（俗称“胃瘫”）是指胃壁肌肉功能异常，导致胃部无法正常将食物排空至小肠。这类药物通过延缓胃排空来控制血糖和减轻体重。然而，MDL 3094 诉讼中的原告称，对某些人而言，这一过程并非仅仅减慢，而是几乎停滞。这会导致持续呕吐、严重营养不良，并对生活质量造成永久性损害。

2026 年 5 月诉讼最新进展

全美相关的联邦案件已并入位于宾夕法尼亚州东区的大规模侵权诉讼 (MDL)，目前由 Karen S. Marston 法官审理。  

• 案件规模： 目前已有超过 3,500 起活跃诉讼被并案处理。  
• 专家证词： 法院正在审查关于“通用因果关系”的专家报告，即探讨此类药物在科学上是否能够导致永久性胃轻瘫。
• “风向标”审判： 首批测试性审判预计将于 2026 年底或 2027 年初开始，其结果将直接影响未来可能的全球性和解。  

即使没有住院，我可以就视力受损索赔吗？

可以。2026 年理赔的一个重要新领域是针对 NAION（非动脉炎性前部缺血性视神经病变）的诉讼。这是一种被称为“眼睛中风”的罕见病症，会导致突然失明。原告指控诺和诺德 (Novo Nordisk) 等公司未能警告用户，司美格鲁肽 (Semaglutide) 可能会损害视神经的血液循环。贝克法律集团坚持以人为本，全面评估药物对客户健康的综合影响，确保每一个受害者都能获得公正。

Ozempic and Gastroparesis: The New Pharmaceutical Mass Tort Frontier

At Becker Law Group, led by veteran trial attorney Todd Becker, we have a long-standing history of protecting individuals from corporate negligence. While our firm is deeply rooted in California wildfire and personal injury law, we are closely monitoring the rapidly evolving national litigation regarding GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro. As of May 2026, thousands of patients are alleging that pharmaceutical giants failed to warn them of severe, life-altering gastrointestinal side effects. Our mission is to ensure that "Your Fight Is Our Fight" as we hold these manufacturers accountable for the safety of the products they market.

What is the Link Between Ozempic and Gastroparesis?

Gastroparesis, commonly known as stomach paralysis, is a condition where the muscles in the stomach wall do not function properly, preventing the stomach from emptying into the small intestine. GLP-1 medications work by slowing gastric emptying to manage blood sugar and induce weight loss. However, plaintiffs in the MDL 3094 litigation allege that for some, this process does not just slow down—it stops. This leads to chronic vomiting, severe malnutrition, and a permanent loss of quality of life.

Status of the GLP-1 MDL 3094 in May 2026

The federal litigation is centralized in the Eastern District of Pennsylvania. Following the passing of Judge Gene E.K. Pratter, the proceedings are now overseen by U.S. District Judge Karen S. Marston. As of May 2026, the litigation has reached a critical stage:

• Caseload: Over 3,500 active lawsuits are currently consolidated.
• Expert Discovery: The court is currently reviewing expert reports on general causation—specifically whether the drugs are scientifically capable of causing permanent gastroparesis.
• Bellwether Schedule: Test trials (bellwether trials) are being prepared for late 2026 and early 2027 to gauge jury responses to the evidence.

Can I File a Lawsuit for Stomach Paralysis?

To qualify for the current mass tort litigation in 2026, claimants typically must meet specific criteria established through recent court rulings:

• Diagnosis: A confirmed diagnosis of gastroparesis, gastric stasis, or ileus while using a name-brand GLP-1 (Ozempic, Wegovy, Rybelsus, Trulicity, or Mounjaro).
• Severity: Evidence of hospitalization or emergency room visits for symptoms like persistent vomiting or severe abdominal pain.
• Diagnostic Proof: Per Judge Marston's recent rulings, objective diagnostic evidence such as a gastric emptying study (scintigraphy) may be required to verify the condition's severity.

Beyond Gastroparesis: Vision Loss and NAION

A significant secondary front in the 2026 litigation involves NAION (Non-arteritic Anterior Ischemic Optic Neuropathy), a rare condition often described as an "eye stroke" that causes sudden blindness. While the gastroparesis claims focus on the gut, a separate group of lawsuits is moving forward alleging that manufacturers failed to warn users that semaglutide could impair blood flow to the optic nerve. Becker Law Group remains committed to a human-centric approach, evaluating the total health impact on our clients.